Active-ingredient Dossier
Valsartan
Active-ingredient Dossier for Valsartan (angiotensin receptor blocker). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: AMLODIPINE/VALSARTAN NOVARTIS
- Brand: DILART
- Brand: PHARMACOR
- Brand: VALTRESTO
- Brand: ENTRESTO
- Brand: AMLODIPINE/VALSARTAN/HCT NOVARTIS
- Therapeutic area: Cardiology
What is
Valsartan Valsartan is an angiotensin receptor blocker.
Australian brands containing
Valsartan — DILART — PHARMACOR — AMLODIPINE/VALSARTAN NOVARTIS — CO-DIOVAN — ARX-SACUBITRIL/VALSARTAN — DIOVAN — MSN-SACUBITRIL/VALSARTAN — OMTRALO — SACUBITRIL/VALSARTAN ALPHAPHARM — SACUBITRIL/VALSARTAN LUPIN — SACUVANCE — APO-AMLODIPINE/VALSARTAN
Therapeutic areas
Valsartan is registered in cardiology, with 16 brands containing this ingredient on the ARTG.
Sponsor landscape
Five sponsors market valsartan in Australia: Arrotex Pharmaceuticals, Novartis Pharmaceuticals, Accelagen, Pharmacor, and Alphapharm.
PBS and regulatory activity
Two brands containing valsartan have PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2024–25 fiscal year, government expenditure on valsartan was $145,846,550.23 across 824,477 scripts. The latest PBAC outcome for valsartan was recorded on 1 July 2019, and the latest AusPAR was published on 26 July 2010.